IL10 and Hyperbilirubinemia: In conclusion, the present study is the first to demonstrate that hyperbilirubinemia elicited by atazanavir improves the anti-oxidant status, reduces IL-10 release, and prevents vascular hyporeactivity during experimental endotoxemia in humans.